about
sameAs
Extracellular phosphorylation of the amyloid β-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease.An arginine/lysine-rich motif is crucial for VCP/p97-mediated modulation of ataxin-3 fibrillogenesis.PGC-1α, a potential therapeutic target for early intervention in Parkinson's diseaseA53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old miceStructural modeling of ataxin-3 reveals distant homology to adaptinsThe transcription factor PITX3 is associated with sporadic Parkinson's diseaseAtaxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylationData protection in biomaterial banks for Parkinson's disease research: the model of GEPARD (Gene Bank Parkinson's Disease Germany).Multiple regions of alpha-synuclein are associated with Parkinson's disease.Genes associated with Parkinson syndrome.Nuclear aggregation of polyglutamine-expanded ataxin-3: fragments escape the cytoplasmic quality control.Transdermal rotigotine for the perioperative management of Parkinson's disease.Neuropsychological features of patients with spinocerebellar ataxia (SCA) types 1, 2, 3, and 6.Extensive transcriptional regulation of chromatin modifiers during human neurodevelopment.Callosal tissue loss in multiple system atrophy--a one-year follow-up study.Olfactory FMRI in patients with Parkinson's disease.Qigong exercise for the symptoms of Parkinson's disease: a randomized, controlled pilot study.A possible genetic link between MTHFR genotype and smoking behaviorSmoking upregulates alpha4beta2* nicotinic acetylcholine receptors in the human brain.Stochastic resonance therapy in Parkinson's disease.Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains.Variants associated with Gaucher disease in multiple system atrophy.Genes implicated in the pathogenesis of spinocerebellar ataxias.PDON: Parkinson's disease ontology for representation and modeling of the Parkinson's disease knowledge domain.The Machado-Joseph Disease Deubiquitinase Ataxin-3 Regulates the Stability and Apoptotic Function of p53Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein.Variants in the 3'UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression.SNCA variants are associated with increased risk for multiple system atrophy.Postural Stability in Parkinson's Disease Patients Is Improved after Stochastic Resonance Therapy.Feasibility of [18F]-2-Fluoro-A85380-PET imaging of human vascular nicotinic acetylcholine receptors in vivoA genome-wide association study in multiple system atrophy.Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humansNonmotor fluctuations: phenotypes, pathophysiology, management, and open issues.Epigenome-wide DNA methylation analysis in siblings and monozygotic twins discordant for sporadic Parkinson's disease revealed different epigenetic patterns in peripheral blood mononuclear cells.DNA methylation in Parkinson's disease.Apolipoprotein E ε4 does not affect cognitive performance in patients with Parkinson's disease.CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3.Inhibition of thioredoxin reductase induces apoptosis in neuronal cell lines: role of glutathione and the MKK4/JNK pathway.The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease.Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3.
P50
Q24300656-FB165123-62BD-4440-B404-66B10CACB6A9Q24307381-8C3F0536-2934-4349-98ED-75018FB449D1Q24597726-B6B9F853-2A98-43F9-A0EC-8303D26EE77AQ27324171-B515DE11-EE77-4383-8349-D69B8D5C84E3Q28218002-F29CE9F9-DC18-48E5-9D8C-61D6678065ACQ28251266-32352EA9-868D-423A-9446-69A4240BBA44Q28566835-4BC796F6-0682-47EA-8A25-BE480E41EC27Q31093699-DFD011D3-1180-4F03-BE76-035723121B66Q31155710-567672CC-75B1-4FF8-8E1B-C3172C547DF5Q33346009-A7D96FCE-14FB-4FA0-A378-479CB9597520Q33673755-21B8F776-F53F-4F3E-994B-BF2BA422601BQ33956617-3A704F33-4D99-4F95-BD46-524A52541A0DQ34173060-3BB7648A-883D-4147-ACF0-785E29A82D70Q34270920-755CBEAC-1A5B-41BF-8EB6-744B24E66377Q34339151-30253EDA-6B9B-420B-8A85-B40BED42A8B4Q34347462-CC0FC79C-07A2-4025-96F1-AAD1ADF569CAQ34460202-4F1B0DD6-3045-4613-A776-97FA7D9F301CQ34535153-E6385226-7A43-479F-8646-F7D355D4F190Q34584792-A3EB80CF-E684-4100-97FC-BFE8ED1B7DBFQ34630755-9FAED3C1-7A8C-4F6F-97E1-FEF5AABE8309Q34660005-E6DACBAE-9BB2-4B5C-B4E2-D41DC60F7388Q35469633-6EC11FD5-C06A-4565-9DE5-6F4283E5E6AEQ35640868-DBDB56F3-34D5-428D-BBC7-3093188FD194Q36086743-31059864-8084-4EE9-8D58-692F9A7F6BC5Q36193918-D38B488B-52AC-454F-B268-94A1E3BDDD31Q36321556-7050CE48-983F-498A-A103-57C7EF281CE6Q36403908-A95890CD-612D-40A2-BEE5-75760483D9F5Q36460907-43B2077B-8077-4FDD-907E-240709490DF3Q36559320-728EF53C-DA80-4BC3-BA00-29F84925A6D9Q36757456-6A9879BC-3EB0-4AF5-BD71-A492329A49D4Q37345458-C3D8D2B2-CFFD-4A63-AA93-4D5C477B00E0Q37369702-95CDCD2B-37BB-4EDE-BF6C-76CF01E3A214Q38658393-36902B54-6B45-4AD1-AEFF-706198C887A7Q38814364-83299A7D-C954-43B1-B4A4-1F4960D624C8Q38819038-A2A243CE-6F06-4A07-B239-BA6204F0699BQ39671039-3CF9D71B-5284-4496-8A83-B4DDB638922EQ39835292-D8FEE0AD-8CCB-4035-903C-F0382E872715Q40121875-E2392C25-841B-48BF-B0B5-2DA4DF0C3472Q40136993-698F3CDB-DEDD-4EE7-8DFD-3E2DBCD3077BQ40623717-0B0F1899-E29F-424A-B070-A3BF18E9CE87
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ullrich Wüllner
@ast
Ullrich Wüllner
@en
Ullrich Wüllner
@es
Ullrich Wüllner
@nl
Ullrich Wüllner
@sl
type
label
Ullrich Wüllner
@ast
Ullrich Wüllner
@en
Ullrich Wüllner
@es
Ullrich Wüllner
@nl
Ullrich Wüllner
@sl
altLabel
Wuellner
@en
Wüllner
@en
prefLabel
Ullrich Wüllner
@ast
Ullrich Wüllner
@en
Ullrich Wüllner
@es
Ullrich Wüllner
@nl
Ullrich Wüllner
@sl
P106
P1153
6504210108
P21
P2798
P31
P4012
P496
0000-0002-3132-0790
P569
2000-01-01T00:00:00Z